Dimensional Fund Advisors LP Buys 31,105 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Dimensional Fund Advisors LP lifted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 13.9% in the second quarter, Holdings Channel reports. The firm owned 255,396 shares of the biotechnology company’s stock after buying an additional 31,105 shares during the period. Dimensional Fund Advisors LP’s holdings in Sarepta Therapeutics were worth $40,353,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in SRPT. Mather Group LLC. acquired a new stake in Sarepta Therapeutics during the 1st quarter worth about $28,000. Riggs Asset Managment Co. Inc. increased its stake in shares of Sarepta Therapeutics by 125.0% in the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 125 shares in the last quarter. Innealta Capital LLC purchased a new position in shares of Sarepta Therapeutics in the 2nd quarter valued at about $31,000. New Covenant Trust Company N.A. purchased a new position in shares of Sarepta Therapeutics in the 1st quarter valued at about $32,000. Finally, GAMMA Investing LLC increased its stake in shares of Sarepta Therapeutics by 37.0% in the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 87 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, September 19th. Cantor Fitzgerald restated a “neutral” rating and set a $152.00 target price on shares of Sarepta Therapeutics in a report on Friday, September 20th. Robert W. Baird upped their price objective on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, June 21st. Citigroup decreased their price objective on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $235.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, June 27th. Three equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $187.39.

Insider Buying and Selling at Sarepta Therapeutics

In related news, Director Michael Andrew Chambers acquired 37,038 shares of the company’s stock in a transaction on Friday, August 16th. The shares were purchased at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the purchase, the director now owns 284,034 shares in the company, valued at $38,003,749.20. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Sarepta Therapeutics news, Director Michael Andrew Chambers purchased 37,038 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were bought at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the purchase, the director now directly owns 284,034 shares in the company, valued at approximately $38,003,749.20. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The disclosure for this sale can be found here. Company insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Up 0.3 %

SRPT stock opened at $124.89 on Tuesday. Sarepta Therapeutics, Inc. has a 12 month low of $55.25 and a 12 month high of $173.25. The firm has a market cap of $11.81 billion, a PE ratio of 1,135.36 and a beta of 0.81. The firm has a 50 day simple moving average of $134.56 and a 200 day simple moving average of $132.86. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.01 by $0.06. The business had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The firm’s quarterly revenue was up 38.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.27) EPS. Equities research analysts forecast that Sarepta Therapeutics, Inc. will post 1.45 earnings per share for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.